Literature DB >> 1727733

Pituitary response to growth hormone-releasing hormone in IDDM. Abnormal responses to insulin and hyperglycemia.

M Press1, S Caprio, W V Tamborlane, R Bhushan, M Thorner, W Vale, J Rivier, R S Sherwin.   

Abstract

In poorly controlled insulin-dependent diabetes mellitus (IDDM), hyperglycemia fails to inhibit the pituitary response to growth hormone-releasing factor (GRF). To evaluate whether this derangement is reversed by a simultaneous elevation of circulating insulin, 0.3 micrograms/kg i.v. GRF 1-40 was administered to nine poorly controlled IDDM subjects (HbA1 greater than 11.1%) with and without concomitant infusion of insulin. In the absence of insulin, the poorly controlled IDDM subjects demonstrated a growth hormone response to GRF similar to that of nondiabetic subjects, despite marked hyperglycemia (approximately 16.8 mM). When insulin was infused into these same patients (insulin clamp) to produce combined hyperinsulinemia (528 +/- 90 pM) and hyperglycemia (16.5 +/- 1.98 mM), the GRF-induced growth hormone rise was markedly exaggerated (65 +/- 11 vs. 20 +/- 4 micrograms/L without insulin infusion, P less than 0.001). This enhancement of GRF-stimulated growth hormone release by insulin was strikingly attenuated (22 +/- 7 micrograms/L) in five well-controlled diabetic subjects studied under conditions of similar hyperinsulinemia (486 +/- 84 pM) and hyperglycemia (16.41 +/- 0.95 mM). In contrast, in nondiabetic subjects, acute hyperinsulinemia reduced the growth hormone response to GRF. We conclude that the failure of hyperglycemia to block the pituitary response to GRF in poorly controlled diabetes is not attributable to the lack of a coincident increase in circulating insulin. The paradoxical stimulatory effect of insulin on GRF-induced growth hormone release may contribute to the high spontaneous growth hormone levels characteristically seen in poorly controlled insulin-treated patients, and its attenuation after intensive insulin therapy may contribute to the reversal of growth hormone hypersecretion in well-controlled diabetic patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1727733     DOI: 10.2337/diab.41.1.17

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  5 in total

Review 1.  Diabetes in puberty.

Authors:  D B Dunger
Journal:  Arch Dis Child       Date:  1992-05       Impact factor: 3.791

2.  The inhibitory effect of glucose on growth hormone secretion is lost in obesity but not in hypertension.

Authors:  P Limone; S E Oleandri; P Ajmone Catt; S Grottoli; C Frangioni; E Avogadri; M Perrin; M R Valetto; M Maccario
Journal:  J Endocrinol Invest       Date:  1997-11       Impact factor: 4.256

3.  The effects of a specific growth hormone antagonist on overnight insulin requirements and insulin sensitivity in young adults with Type 1 diabetes mellitus.

Authors:  R M Williams; R Amin; F Shojaee-Moradie; A M Umpleby; C L Acerini; D B Dunger
Journal:  Diabetologia       Date:  2003-07-24       Impact factor: 10.122

4.  Variability in the growth hormone response to growth hormone-releasing hormone alone or combined with pyridostigmine in type 1 diabetic patients.

Authors:  A Giustina; C Bodini; S Bossoni; U Valentini; W B Wehrenberg
Journal:  J Endocrinol Invest       Date:  1993-09       Impact factor: 4.256

5.  A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans.

Authors:  M L Hartman; P E Clayton; M L Johnson; A Celniker; A J Perlman; K G Alberti; M O Thorner
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.